D
Daniel Skovronsky
Researcher at Avid Radiopharmaceuticals
Publications - 84
Citations - 9604
Daniel Skovronsky is an academic researcher from Avid Radiopharmaceuticals. The author has contributed to research in topics: Alzheimer's disease & Cognitive decline. The author has an hindex of 40, co-authored 81 publications receiving 8355 citations. Previous affiliations of Daniel Skovronsky include Eli Lilly and Company & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
TL;DR: Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Journal ArticleDOI
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark,Michael J. Pontecorvo,Thomas G. Beach,Barry J. Bedell,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Eric M. Reiman,Marwan N. Sabbagh,Carl H. Sadowsky,Julie A. Schneider,Anupa Arora,Alan Carpenter,Matthew Flitter,Abhinay D. Joshi,Michael J. Krautkramer,Ming Lu,Mark A. Mintun,Daniel Skovronsky +18 more
TL;DR: The results of this study validate the binary visual reading method approved in the USA for clinical use with flor betapir and suggest that florbetapir could be used to distinguish individuals with no or sparse amyloid plaques from those with moderate to frequent plaques.
Journal ArticleDOI
Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
Christopher C. Rowe,Uwe Ackerman,William J Browne,Rachel S. Mulligan,Kerryn L Pike,Graeme O'Keefe,H. J. Tochon-Danguy,Gordon Chan,Salvatore U Berlangieri,Gareth Jones,Kerryn L Dickinson-Rowe,H Kung,Wei Zhang,Mei-Ping Kung,Daniel Skovronsky,Thomas Dyrks,Gerhard Holl,Sabine Krause,Matthias Friebe,Lutz Lehman,Stefanie Lindemann,Ludger Dinkelborg,Colin L. Masters,Victor L. Villemagne +23 more
TL;DR: F-BAY94-9172 PET discriminates between AD and FTLD or healthy controls and might facilitate integration of Abeta imaging into clinical practice.
Journal ArticleDOI
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
Dean F. Wong,Paul B. Rosenberg,Yun Zhou,Anil Kumar,Vanessa Raymont,Hayden T. Ravert,Robert F. Dannals,Ayon Nandi,James Robert Brašić,Weiguo Ye,John Hilton,Constantine G. Lyketsos,Hank F. Kung,Abhinay Joshi,Daniel Skovronsky,Daniel Skovronsky,Michael Pontecorvo +16 more
TL;DR: 18F-AV-45 was well tolerated, and PET showed significant discrimination between AD patients and HCs, using either a parametric reference region method (DVR) or a simplified SUVR calculated from 10 min of scanning 50–60 min after 18F- AV-45 administration.
Journal ArticleDOI
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
William E. Klunk,William E. Klunk,Robert A. Koeppe,Julie C. Price,Tammie L.S. Benzinger,Tammie L.S. Benzinger,Michael D. Devous,William J. Jagust,Keith A. Johnson,Chester A. Mathis,Davneet S. Minhas,Michael J. Pontecorvo,Christopher C. Rowe,Daniel Skovronsky,Mark A. Mintun +14 more
TL;DR: A working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls and typical Alzheimer's disease patients.